Characterizing HCV primary resistance mutations for direct acting antiviral drug (DAA)

• Grant number: 17/01809-9
• Support Opportunities: Regular Research Grants
• Start date: August 01, 2017
• End date: July 31, 2019
• Field of knowledge: Biological Sciences - Microbiology
• Principal Investigator: Regina Célia Moreira
• Grantee: Regina Célia Moreira
• Host Institution: Instituto Adolfo Lutz (IAL). Coordenadoria de Controle de Doenças (CCD). Secretaria da Saúde (São Paulo - Estado). São Paulo , SP, Brazil
• Associated researchers: Fernanda de Mello Malta ; Gaspar Lisboa Neto ; João Renato Rebello Pinho ; Marcilio Figueiredo Lemos ; Maria Cássia Jacintho Mendes Corrêa

Abstract

Chronic infection with hepatitis C virus affects about 160 million people worldwide and it is leading cause of cirrhosis and other complications. The recent understanding HCV life cycle make possible the development of new drugs; target the viral replication process, such structural proteins like NS3/NS5A and NS5B. Direct acting antiviral drug (DAA) promises to open a new era in treating chronic HCV The emergence of drug-resistant strains of HCV has resulted in the failure of many therapeutic strategies. The aim of this study was to screen resistance mutations for responses for direct acting antiviral drug NS3/ NS5A and NS5B in samples from patients following in a public health laboratory in the State of São Paulo, before the beginning the therapy. Will include a samples of serum from patients with chronic HCV infection, genotyping 1a and 1b, who were starting or following-up public health service treatment and they had never received treatment. PCR and sequence from specifically genome fragment will be done from HCV. (AU)

Scientific publications

(4)

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

ANA PAULA DE TORRES SANTOS; VANESSA CRISTINA MARTINS SILVA; MARIA CÁSSIA MENDES-CORRÊA; MARCILIO FIGUEIREDO LEMOS; FERNANDA DE MELLO MALTA; RÚBIA ANITA FERRAZ SANTANA; GREGÓRIO TADEU FERNANDO DASTOLI; VANESSA FUSCO DUARTE DE CASTRO; JOÃO RENATO REBELLO PINHO; REGINA CÉLIA MOREIRA. Characterization of primary direct-acting antiviral (DAA) drugs resistance mutations in NS5A/NS5B regions of hepatitis C virus with genotype 1a and 1b from patients with chronic hepatitis. Revista do Instituto de Medicina Tropical de São Paulo, v. 64, 2022-09-30. (17/01809-9)

MOREIRA, REGINA CELIA; DE TORRES SANTOS, ANA PAULA; LISBOA-NETO, GASPAR; JACINTHO MENDES-CORREA, MARIA CASSIA; LEMOS, MARCILIO FIGUEIREDO; MALTA, FERNANDA MELLO; FERRAZ SANTANA, RABIA ANITA; FERNANDO DASTOLI, GREGORIO TADEU; DUARTE DE CASTRO, VANESSA FUSCO; REBELLO PINHO, JOAO RENATO. Prevalence of naturally occurring amino acid substitutions associated with resistance to hepatitis C virus NS3/NS4A protease inhibitors in Sao Paulo state. ARCHIVES OF VIROLOGY, v. 163, n. 10, p. 2757-2764, OCT 2018. (17/01809-9)

BRÍGIDA HELENA DA SILVA MENEGHELLO; MÁRCIA MARIA COSTA NUNES SOARES; VANESSA CRISTINA MARTINS SILVA; MARCILIO FIGUEIREDO LEMOS; MURILO CASTRO CERVATO; JOÃO CAETANO FILHO; ROBERTA SITNIK; TÂNIA CRISTINA HIGINO ESTÉCIO; ADRIANA PARISE COMPRI; JOÃO RENATO REBELLO PINHO; et al. Hepatitis B in the Northwestern region of Sao Paulo State: genotypes and resistance mutations. Revista do Instituto de Medicina Tropical de São Paulo, v. 63, 2021-11-08. (17/01809-9)

DE TORRES SANTOS, ANA PAULA; MARTINS SILVA, VANESSA CRISTINA; MENDES-CORREA, MARIA CASSIA; LEMOS, MARCILIO FIGUEIREDO; MALTA, FERNANDA DE MELLO; FERRAZ SANTANA, RUBIA ANITA; FERNANDO DASTOLI, GREGORIO TADEU; DUARTE DE CASTRO, VANESSA FUSCO; REBELLO PINHO, JOAO RENATO; MOREIRA, REGINA CELIA. Prevalence and Pattern of Resistance in NS5A/NS5B in Hepatitis C Chronic Patients Genotype 3 Examined at a Public Health Laboratory in the State of Sao Paulo, Brazil. INFECTION AND DRUG RESISTANCE, v. 14, p. 723-730, 2021. (17/01809-9)